Loading...

Asterias Biotherapeutics

DB:9XA
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9XA
DB
€53M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

As of March 8, 2019, operates as a subsidiary of BioTime, Inc. The last earnings update was 122 days ago. More info.


Add to Portfolio Compare Print
  • Asterias Biotherapeutics has significant price volatility in the past 3 months.
9XA Share Price and Events
7 Day Returns
4.8%
DB:9XA
-4.5%
DE Biotechs
-1.4%
DE Market
1 Year Returns
-46.3%
DB:9XA
-11%
DE Biotechs
-10.6%
DE Market
9XA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Asterias Biotherapeutics (9XA) 4.8% 13.9% 3.4% -46.3% -83% -
DE Biotechs -4.5% -2.8% -6.7% -11% 65.5% 3.2%
DE Market -1.4% 3.9% 5.7% -10.6% 8.5% 12.7%
1 Year Return vs Industry and Market
  • 9XA underperformed the Biotechs industry which returned -11% over the past year.
  • 9XA underperformed the Market in Germany which returned -10.6% over the past year.
Price Volatility
9XA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Asterias Biotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Asterias Biotherapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.827.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Asterias Biotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Asterias Biotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9XA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.37
DB:9XA Share Price ** DB (2019-03-08) in EUR €0.83
DB:9XA Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.123 $0.93
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 22.18x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 18.52x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Asterias Biotherapeutics.

DB:9XA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:9XA Share Price ÷ EPS (both in USD)

= 0.93 ÷ -0.37

-2.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Asterias Biotherapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Asterias Biotherapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Asterias Biotherapeutics's expected growth come at a high price?
Raw Data
DB:9XA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-10.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.29x
Germany Market PEG Ratio Median Figure of 278 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Asterias Biotherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Asterias Biotherapeutics's assets?
Raw Data
DB:9XA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.44
DB:9XA Share Price * DB (2019-03-08) in EUR €0.83
DB:9XA Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.123 $0.93
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.72x
Germany Market PB Ratio Median Figure of 567 Publicly-Listed Companies 1.75x
DB:9XA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:9XA Share Price ÷ Book Value per Share (both in USD)

= 0.93 ÷ 0.44

2.11x

* Primary Listing of Asterias Biotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Asterias Biotherapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Asterias Biotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Asterias Biotherapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Asterias Biotherapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-10.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Asterias Biotherapeutics expected to grow at an attractive rate?
  • Unable to compare Asterias Biotherapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Asterias Biotherapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Asterias Biotherapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:9XA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:9XA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -10.6%
DB:9XA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 69.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 29%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9XA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9XA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 31 -27 1
2022-12-31 11 -46 1
2021-12-31 1 -35 1
2020-12-31 0 -31 1
2019-12-31 0 -27 1
2018-12-31 1 -19 1
DB:9XA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 1 -16 -20
2018-06-30 2 -17 -23
2018-03-31 3 -21 -24
2017-12-31 4 -24 -28
2017-09-30 6 -23 -31
2017-06-30 6 -23 -35
2017-03-31 7 -22 -31
2016-12-31 7 -19 -35
2016-09-30 6 -19 -31
2016-06-30 5 -18 -24
2016-03-31 4 -16 -22
2015-12-31 4 -12 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Asterias Biotherapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Asterias Biotherapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9XA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Asterias Biotherapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9XA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31
DB:9XA Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.37
2018-06-30 -0.42
2018-03-31 -0.47
2017-12-31 -0.56
2017-09-30 -0.64
2017-06-30 -0.75
2017-03-31 -0.69
2016-12-31 -0.83
2016-09-30 -0.76
2016-06-30 -0.61
2016-03-31 -0.60
2015-12-31 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Asterias Biotherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Asterias Biotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Asterias Biotherapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Asterias Biotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Asterias Biotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Asterias Biotherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Asterias Biotherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Asterias Biotherapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Asterias Biotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Asterias Biotherapeutics Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9XA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.73 -20.30 7.54 17.19
2018-06-30 2.30 -22.65 7.67 20.30
2018-03-31 2.51 -24.40 7.53 23.67
2017-12-31 4.04 -28.37 10.09 26.64
2017-09-30 5.77 -31.17 10.76 28.08
2017-06-30 6.15 -35.01 12.93 26.69
2017-03-31 7.37 -31.44 13.66 25.72
2016-12-31 6.95 -35.49 15.48 25.47
2016-09-30 5.81 -31.05 15.91 23.00
2016-06-30 5.16 -23.91 13.26 22.39
2016-03-31 4.40 -22.37 12.52 20.07
2015-12-31 3.58 -15.00 7.90 17.32
2015-09-30 4.03 -13.42 6.24 17.32
2015-06-30 2.69 -11.60 6.16 15.26
2015-03-31 1.94 -10.78 5.86 14.30
2014-12-31 1.22 -10.10 5.28 13.31
2014-09-30 0.17 -24.34 5.10 10.30
2014-06-30 0.08 -25.32 5.16 8.88
2014-03-31 0.06 -23.85 4.36 6.73
2013-12-31 -22.38 3.88 4.32
2012-12-31 -3.04 3.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Asterias Biotherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Asterias Biotherapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Asterias Biotherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Asterias Biotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Asterias Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Asterias Biotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Asterias Biotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Asterias Biotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Asterias Biotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Asterias Biotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 985.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Asterias Biotherapeutics Company Filings, last reported 5 months ago.

DB:9XA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 24.51 0.02 12.59
2018-06-30 28.07 3.25 14.81
2018-03-31 33.00 3.38 18.80
2017-12-31 33.54 3.52 21.60
2017-09-30 31.73 3.65 20.72
2017-06-30 36.72 3.77 25.02
2017-03-31 44.46 3.89 32.50
2016-12-31 42.03 4.01 35.07
2016-09-30 42.73 4.12 33.93
2016-06-30 43.27 4.23 32.21
2016-03-31 33.33 4.33 19.52
2015-12-31 45.10 4.43 28.19
2015-09-30 42.17 4.09 24.21
2015-06-30 46.67 3.33 29.63
2015-03-31 38.53 0.56 26.57
2014-12-31 32.63 0.38 17.45
2014-09-30 33.90 0.00 24.70
2014-06-30 33.70 0.00 32.59
2014-03-31 48.99 0.00 41.86
2013-12-31 53.78 0.00 49.79
2012-12-31 -0.76 0.00
  • Asterias Biotherapeutics's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Asterias Biotherapeutics has less than a year of cash runway based on current free cash flow.
  • Asterias Biotherapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.5% each year.
X
Financial health checks
We assess Asterias Biotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Asterias Biotherapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Asterias Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Asterias Biotherapeutics dividends.
If you bought €2,000 of Asterias Biotherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Asterias Biotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Asterias Biotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9XA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9XA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Asterias Biotherapeutics has not reported any payouts.
  • Unable to verify if Asterias Biotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Asterias Biotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Asterias Biotherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Asterias Biotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Asterias Biotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Asterias Biotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Asterias Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Mulroy
COMPENSATION $2,617,279
AGE 52
TENURE AS CEO 1.8 years
CEO Bio

Mr. Michael H. Mulroy, also known as Mike, serves as the President of Mulroy Advisors, LLC. Mr. Mulroy has been the Chief Executive Officer and President at Asterias Biotherapeutics, Inc since June 26, 2017. He has experience as a strategic planner and as legal counsel and member of a senior management team of a growing biopharmaceutical company. Mr. Mulroy has experience in corporate finance and investor relations. He served as a Senior Advisor to CamberView Partners, LLC. Mr. Mulroy served as Executive Vice President of Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc until September 2014. He served as an Executive Vice President of Strategic Affairs at Questcor Pharmaceuticals, Inc. since February 17, 2014. Mr. Mulroy served as General Counsel and Secretary of Questcor Pharmaceuticals, Inc. since January 2011 and corporate counsel since 2005. At Questcor, Mr. Mulroy served in various capacities from January 2011 to September 2014. He served as the Chief Financial Officer of Questcor Pharmaceuticals, Inc. from January 2011 to February 17, 2014; as Executive Vice President from July 31, 2013 to February 17, 2014 and Principal Accounting Officer from September 26, 2011 to February 17, 2014. He was a Partner of Stradling Yocca Carlson & Rauth, P.C since 2004. He served at Stradling Yocca from 2003 to 2011, where he represented Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an Investment Banker at Merrill Lynch and Citigroup from 1997 to 2003, where he advised healthcare companies and other clients across a range of industries in connection with corporate finance and strategic transactions. He has been an Independent Director of BioTime, Inc. since October 06, 2014. He served as Director of Asterias Biotherapeutics, Inc. from June 26, 2017 to March 8, 2019. He serves as a Director of privately-held Magtrol Inc. He serves as a Director of AgeX Therapeutics, Inc. since January 2017. He served as an Independent Director of Comarco, Inc. from July 21, 2011 to August 25, 2014. Mr. Mulroy is a Member of the State Bar of California and the Orange County Bar Association, Business Section. He is a business consultant. He earned his J.D. Degree from the University of California, Los Angeles and his B.A. in Economics from the University of Chicago.

CEO Compensation
  • Insufficient data for Michael to compare compensation growth.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Asterias Biotherapeutics management team in years:

1.8
Average Tenure
52.5
Average Age
  • The average tenure for the Asterias Biotherapeutics management team is less than 2 years, this suggests a new team.
Management Team

Michael Mulroy

TITLE
CEO & President
COMPENSATION
$3M
AGE
52
TENURE
1.8 yrs

Ed Wirth

TITLE
Chief Medical Officer
COMPENSATION
$778K
AGE
53
TENURE
6 yrs

Katy Spink

TITLE
Consultant
COMPENSATION
$831K
AGE
44
TENURE
1.2 yrs

Steve Cartt

TITLE
COMPENSATION
$766K
AGE
55
TENURE
1.8 yrs

Ryan Chavez

TITLE
CFO & General Counsel
AGE
42
TENURE
2.3 yrs

Craig Halberstadt

TITLE
Senior Vice President of Research & Product Development
TENURE
1.2 yrs

Jane Lebkowski

TITLE
Scientific Advisor
COMPENSATION
$854K
AGE
62
TENURE
1.3 yrs
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Asterias Biotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Asterias Biotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

As of March 8, 2019, operates as a subsidiary of BioTime, Inc.

Details
Name: Asterias Biotherapeutics, Inc.
9XA
Exchange: DB
Founded: 2012
€52,597,456
55,658,684
Website: http://www.asteriasbiotherapeutics.com
Address: Asterias Biotherapeutics, Inc.
6300 Dumbarton Circle,
Fremont,
California, 94555,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB 9XA Series A Common Stock Deutsche Boerse AG DE EUR 08. Oct 2014
Number of employees
Current staff
Staff numbers
31
Asterias Biotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/11 21:45
End of day share price update: 2019/03/08 00:00
Last estimates confirmation: 2019/03/08
Last earnings filing: 2018/11/09
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.